Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- China Medical Reports Positive Results for Ongoing Business
- ChinaBio Today submits: As promised earlier, China Medical Technologies CMED released selected Q2 (ended September 30, 2008) results, though a full disclosure, complete with analysts’ call, will wait until December 18. The problem with a full release is reporting issues: China Medical is deciding how to account for its...
- External links 2008-11-18
- Tongjitang Shares React Well to Buyback News
- ChinaBio Today submits: Tongjitang Chinese Medicines Company TCM announced its shareholders approved a $20 million share buyback program at the company’s general meeting. The resolution calls for the company to complete a purchase of “up to” $20 million worth of its ADSs within the next 18 months. The program...
- External links 2008-11-04
- 3SBio's Q3 Hurt by Lehman Bankruptcy
- ChinaBio Today submits: 3SBio Inc. SSRX announced a $2.7 million writedown as a consequence of the U.S. financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers...
- External links 2008-11-04
- China Sky One Expands into Injected Drugs
- ChinaBio Today submits: China Sky One Medical CSKI received SFDA approval for two new products. Sodium ferulate by injection, a TCM found in the root of Angelica sinensis, is indicated for cardiovascular disease. The drug inhibits the gathering of hematoblasts and stretches blood vessels in order to protect cardiac...
- External links 2008-10-31
- China Sky One Adds Breast Lesion Drug to Product Portfolio
- ChinaBio Today submits: China Sky One Medical CSKI has bought a proprietary breast lesion drug from Harbin Medical University for 10 million RMB ($1.5 million). The drug, which China Sky One and Harbin developed jointly, has completed its Phase I trial. In the more than 10,000 patients enrolled in...
- External links 2008-10-30
- China Medical Wrestles with Daunting $345 Million Acquisition
- ChinaBio Today submits: China Medical Technologies CMED told investors it would release a preliminary Q2 (ended September 30, 2008) financial report on November 18, but a full announcement, complete with answering questions from analysts, will wait another month until December 18. As reason for the delay, the company said...
- External links 2008-10-27
- American Oriental Announces Two Acquisitions
- ChinaBio Today submits: American Oriental Bioengineering, Inc. AOB completed two acquisitions while, at the same time, announcing it had declined to pursue a third. In August, AOB had announced a signed letter of intent to pay $110 million to acquire an unnamed China pharmaceutical distributor with $550 million in...
- External links 2008-10-23
- WuXi Misses Q3 Forecast, Guides Lower for Year
- ChinaBio Today submits: WuXi PharmaTech WX released weaker-than-expected financial Q3 results unaudited and, at the same time, lowered guidance for its full year. The company reduced its forecast for 2009 revenue by $20 to $35 million. The new revenue range is expected to be between $260 and $265 million,...
- External links 2008-10-15
- Roche Intent on Discovering Innovative Medicines in China
- ChinaBio Today submits: Roche (RHHBY.PK) has broken ground on an expansion of its facilities at its site in Shanghai’s Zhangjiang Hi-Tech Park, an ambitious expansion that seeks to provide the backbone for the next ten years of the company’s China growth. In addition, Roche has established an office for...
- External links 2008-11-04
- Investors Liked What They Saw in Simcere's Q3 Report
- ChinaBio Today submits: Simcere Pharmaceutical Group SCR released very positive unaudited financial results for its third quarter. At the same time, the company said it would begin a $50 million share buyback. At the end of the quarter, Simcere reported cash and short-term investments of 831 million RMB ($122.4...
- External links 2008-11-06
- Genesis Pharma Reports Improved Q1
- ChinaBio Today submits: Genesis Pharmaceuticals Enterprises, Inc. (GNPH.OB) reported that Q1 (ended September 30, 2008) revenues climbed an admirable 66% to $27.6 million, and gross profit rose an even more dramatic 81% to $21.8 million. On a non-GAAP basis, Genesis reported net income of $4.8 million a 50% increase....
- External links 2008-11-18
- China Med Forecasts Increased Revenues for 2009 Despite Low Q3
- ChinaBio Today submits: China Medicine Corporation (CHME.OB) said a delay in a provincial bidding system caused its Q3 revenues to fall 17% to $10.5 million. Even though margins rose slightly, the increases were not enough to offset Q3’s lower revenues. As a result, net income dipped 10% to $2...
- External links 2008-11-16
- Nine New Drugs for China Sky One
- ChinaBio Today submits: China Sky One Medical, Inc. CSKI has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million). The company estimates the nine products will generate $5 million in revenue during 2009. According to China...
- External links 2008-11-13
- China Biologic's Q3: Still Going Strong
- ChinaBio Today submits: China Biologic Products (CBPO.OB), enjoying higher prices for its products and lower operating expenses, reported a very substantial 54% rise in Q3 revenues to $13.8 million. Net income climbed an even larger 98% to $4.5 million, which works out to 21 cents per share, fully diluted....
- External links 2008-11-13
- BMP Sunstone's Q3: Revenues on the Rise
- ChinaBio Today submits: BMP Sunstone Corporation BJGP, a company that has been building itself through acquisitions over the last two years, announced very strong Q3 results. It was the first quarter in which results included participation from BMP Sunstone’s acquisition of drug distributor Rongheng. Sunstone announced it acquired a...
- External links 2008-11-12
- Tinayin Reports Higher Revenue and Costs
- ChinaBio Today submits: Tianyin Pharmaceutical Co. TPI reported higher results for the first quarter of 2009 fiscal year. Revenues rose 33 % to $9.6 million, while net income increased at a slower pace, rising 11% to $1.8 million. However, because the number of shares outstanding almost doubled to 24.6...
- External links 2008-11-11
- Mindray's Q3 Leaves Investors Less Than Pleased
- ChinaBio Today submits: On the face of it, the Q3 financial report issued by Mindray Medical International MR was very positive. Revenues were up 94% at $146.5 million and non-GAAP net income climbed a smaller but still respectable 48% to $33.7 million. Nevertheless, Mindray’s stock price suffered in the...
- External links 2008-11-11
- China Pharma Reports Improved Q3, Accounts Receivable Also Up
- ChinaBio Today submits: China Pharma Holdings (CPHI.OB) reported its Q3 revenues climbed 52% to $12.61 million and net income was up 38% to $4.25 million, which equates to 10 cents per share fully diluted. Growth...
- External links 2008-11-11
- American Oriental Books Another Solid Quarter
- ChinaBio Today submits: American Oriental Bioengineering AOB announced another solid financial performance in Q3. The company’s revenues rose 62% to $70.6 million, and net income was higher by 38% at $16.5 million or 21 cents per diluted share. According to the company, net income failed to keep pace with...
- External links 2008-11-11
- Charles River Blames Slowdown on Biopharmas' Need to Conserve Cash
- ChinaBio Today submits: Charles River Labs CRL reduced its 2008 profit guidance by 3% because its CRO clients are delaying scheduled tests until next year. The trend caused a small slowing of the company’s growth rate in Q3, but the effect in Q4 will be more pronounced, according to...
- External links 2008-11-08
- << Previous
- page 1 of 2
- Next >>
Refining Tags
- Seeking Alpha (23 results)
- China (19 results)
- Operational Accounting (11 results)
- Revenue (9 results)
- Financial Accounting (9 results)
- Investment (9 results)
- Mergers & Acquisitions (7 results)
- Net Income (6 results)
- GAAP (5 results)
- Corporate Law (5 results)
- Business Operations (5 results)
- Acquisition (4 results)
- Drug (4 results)
- China Sky One Medical Inc. (4 results)
- Pharmaceutical Company (3 results)
- Sales Strategy (3 results)
- Healthcare (3 results)
- Sales (3 results)
- Biotech (3 results)
- Investor (3 results)
Presented by American Express